Livagen vs PQQ
A side-by-side research comparison of Livagen and PQQ across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Livagen | PQQ |
|---|---|---|
| Full name | Livagen (Lys-Glu-Asp-Ala Liver/Lymphocyte Bioregulator) | Pyrroloquinoline Quinone (BioPQQ) |
| Category | Detox & Antioxidant | Detox & Antioxidant |
| Status | Research compound (peptide bioregulator) | Dietary supplement (GRAS) |
| Mechanism | As a signal peptide (Lys-Glu-Asp-Ala), it is proposed to decondense chromatin (heterochromatin) in lymphocytes and regulate gene expression in hepatic tissue, supporting liver function and cellular activity. | Activates PGC-1α (master mitochondrial biogenesis regulator) via CREB phosphorylation. Catalytic antioxidant that undergoes 20,000+ redox cycles vs one-time use of vitamin C. Stimulates NGF synthesis for neuroprotection. |
| Molecular weight | ~460 Da | 330.21 Da |
| Half-life | Short (peptide) | ~3-5 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~60% oral |
| Typical dose | ~1-2 capsules/day or short injectable courses | 10-20 mg |
| Frequency | Once daily | Daily |
| Route | Oral capsule or subcutaneous | Oral capsule |
Livagen reported benefits
- Liver function support
- Lymphocyte chromatin activation (proposed)
- Detox/antioxidant support
- Short course-based protocol
PQQ reported benefits
- Mitochondrial biogenesis (new mitochondria)
- Potent antioxidant (catalytic)
- Nerve growth factor stimulation
- Improved sleep quality
- Enhanced cognitive function
- Cellular energy optimization
Related comparisons
Research and educational reference only. Not medical advice.